Henry Sy, PHARMD in Bullhead, AZ - Pharmacist

Henry Sy, PHARMD is a Pharmacist based in Bullhead, Arizona. Henry Sy is licensed to practice in Arizona (license number S022076) and his current practice location is 2360 Az-95, Bullhead, Arizona. He can be reached at his office (for appointments etc.) via phone at (928) 763-5858.

NPI number for Henry Sy is 1396297123 and his current mailing address is 1570 Paseo Grande, Bullhead City, Arizona. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1396297123.

Contact Information

	Henry Sy, PHARMD
	2360 Az-95, Bullhead, AZ 86442
	(928) 763-5858
	Not Available

Healthcare Provider's Profile

Full Name	Henry Sy
Gender	Male
Speciality	Pharmacist
Location	2360 Az-95, Bullhead, Arizona
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1396297123
Provider Enumeration Date: 10/27/2016
Last Update Date: 10/27/2016

Medical Identifiers

Medical identifiers for Henry Sy such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1396297123	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	S022076 (Arizona)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Henry Sy is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Henry Sy, PHARMD 1570 Paseo Grande, Bullhead City, AZ 86442-8523 Ph: () -	Henry Sy, PHARMD 2360 Az-95, Bullhead, AZ 86442 Ph: (928) 763-5858

News Archive

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

Preventing deaths among women globally

In this audio report from United Nations Radio, Marleen Temmerman, head of the Department of Reproductive Health and Research at the WHO, talks to the U.N.'s Beng Poblete-Enriquez about preventable deaths among women globally.

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy, a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.

Hedgehog-signaling inhibitor may shift tumor-associated macrophages back to cancer fighters

A form of cell communication called hedgehog signaling is vital for embryonic development in mammals.

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

Henry Sy, PHARMD - Pharmacist in Bullhead, AZ